PharmaDrug says it aims to file provisional patent for treatment of glaucoma later this year

PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) CEO Daniel Cohen joined Proactive’s Stephen Gunnion with the news that the company aims to file a provisional patent describing novel therapeutic and delivery device for the treatment of glaucoma in the fourth quarter of this year.

Cohen telling Proactive that PharmaDrug has selected a final lead drug candidate from a short list of six DMT analogues.

With the sale of its German business and a focused biotech strategy now in place, Cohen said PharmaDrug can accelerate its push forward in its psychedelic programs.

© 2022 The Latest StockMarket News and Interviews